Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis DOI Creative Commons

Chengdong Xia,

Yufeng Han, Chunhui Yin

и другие.

Frontiers in Endocrinology, Год журнала: 2023, Номер 14

Опубликована: Сен. 15, 2023

Aim This study aims to assess the association between sodium–glucose cotransporter type-2 inhibitor (SGLT-2i) treatment and muscle atrophy in patients with type 2 diabetes mellitus (T2DM). Methods We searched six databases from 1 January 2012 May 2023, without language restrictions. The primary outcome was muscle. Secondary outcomes were weight loss, weakness, malaise, or fatigue. Subgroup analyses performed according different definitions of muscle, duration, measurement methods. quality studies assessed using Cochrane tool. evidence Grading Recommendations, Assessment, Development Evaluations (GRADE) Results Nineteen randomized controlled trials (RCTs) involving 1,482 participants included. Compared control group, a meta-analysis showed that T2DM group treated SGLT-2i demonstrated statistically significant reductions lean body mass 0.66 (95% confidence interval (CI), −1.05 −0.27; p = 0.0009) skeletal 0.35 CI, −0.66 −0.04; 0.03). No deaths serious adverse events reported. included low. Conclusions may lead reduction strength compared group. However, there is still lack high-quality evaluate caused by SGLT-2i. Systematic review registration https://inplasy.com/inplasy-2022-12-0061/ , identifier 2022120061.

Язык: Английский

Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials DOI Creative Commons
Yanli Niu, Ye Zhang, Zhiyong Song

и другие.

Iranian Journal of Public Health, Год журнала: 2024, Номер unknown

Опубликована: Фев. 18, 2024

Background: We systematically reviewed and analyzed the efficacy safety of insulin degludec/insulin aspart (IDegAsp) versus biphasic 30 (BIAsp 30) in patients with type 2 diabetes (T2D). Methods: used computers to search Embase, PubMed, Clinical Trials, Cochrane Library database, collected randomized controlled trials (RCTs) on treatment IDegAsp BIAsp T2D patients. The research period was from establishment database May 19, 2023. Review Manager 5.20 statistical software for systematic meta-analysis. Results: included 8 RCTs 2281 participants. better BIAsp30 improving fasting plasma glucose (FPG) levels (P<0.001) reducing endpoint daily average dose (P<0.01). Furthermore, compared BIAsp30, significantly reduced risk nocturnal hypoglycemic events (P<0.001). However, there no significant difference improvement body weight change (P=0.99), glycosylated hemoglobin (P=0.50), overall (P=0.57) adverse (P=0.89) between two groups. Conclusion: Compared could reduce FPG levels, dosage, patients, without increasing events.

Язык: Английский

Процитировано

2
Role of Muscle Ultrasound for the Study of Frailty in Elderly Patients with Diabetes: A Pilot Study DOI Creative Commons
Andreu Simó-Servat, Ernesto Guevara, Verónica Perea

и другие.

Biology, Год журнала: 2023, Номер 12(6), С. 884 - 884

Опубликована: Июнь 19, 2023

Sarcopenia and diabetes contribute to the development of frailty. Therefore, accessible methods, such as muscle ultrasounds (MUSs), screen for sarcopenia should be implemented in clinical practice.We conducted a cross-sectional pilot study including 47 patients with (mean age: 77.72 ± 5.08 years, mean weight: 75.8 kg 15.89 kg, body mass index: 31.19 6.65 kg/m2) categorized frail by FRAIL Scale or Clinical Frailty confirmed Fried's Phenotype Rockwood's 36-item Index. We used SARC-F questionnaire identify sarcopenia. The Short Physical Performance Battery (SPPB) Timed Up Go (TUG) tests were assess physical performance risk falls, respectively. In addition, other variables measured: fat-free (FFM) Risk Index (SRI) bioimpedance analysis (BIA); thigh thickness (TMT) quadriceps MUS; hand-grip strength dynamometry.We observed correlations between FFM (R = -0.4; p < 0.002) -0.5; 0.0002), well TMT right leg 0.4; 0.02) SRI 0.6; 0.0001). could predict using logistic regression model ROC curve (AUC 0.78) FFM, handgrip strength, TMT. optimal cut-off point maximum efficiency was 1.58 cm (sensitivity 71.4% specificity 51.5%). However, we did not observe differences among groups greater/less frailty based on SARC-F, SPPB, TUG (p > 0.05).MUSs, which correlated BIA 0.02), complemented diagnosis, identifying regional improving AUC 0.78. diagnosis obtained. Larger studies validate MUS technique screening strategy are warranted.

Язык: Английский

Процитировано

6
The outcome of frailty in older people with diabetes as a function of glycaemic control and hypoglycaemic therapy: a review DOI
Grace Keegan, Namita Bhardwaj,

Ahmed H. Abdelhafiz

и другие.

Expert Review of Endocrinology & Metabolism, Год журнала: 2023, Номер 18(5), С. 361 - 375

Опубликована: Июль 20, 2023

Introduction Frailty is an emerging and newly recognized complication of diabetes in older people. However, frailty not thoroughly investigated outcome studies.Areas covered This manuscript reviews the effect glycemic control hypoglycemic therapy on incidence people with diabetes.Expert opinion Current studies show that both low glycemia high are associated frailty. most studies, especially cross-sectional or retrospective, suggesting association, rather than causation, In addition, frail patients characterized by lower body weight mass index (BMI), contrary to those who either overweight obese. may suggest has a heterogeneous metabolic spectrum, starting anorexic malnourished (AM) phenotype at one end, which sarcopenic obese (SO) other glycemia. The current little evidence suggests poor increases risk frailty, but there paucity tight would reduce incident Metformin only well-studied agent, so far, have protective against independent non-frail diabetes. once developed, choice best agent for these will be affected For example, sodium glucose transporter-2 (SGLT-2) inhibitors glucagon-like peptide-1 receptor agonists (GLP-1RA) appropriate SO due their losing properties, while insulin considered early AM its anabolic gaining benefits. Future still required further investigate effects diabetes, determine HbA1c target, explore suitable each

Язык: Английский

Процитировано

4
The predictive values of admission characteristics for 28-day all-cause mortality in septic patients with diabetes mellitus: a study from the MIMIC database DOI Creative Commons

Chengyu Yang,

Yu Jiang,

Cailin Zhang

и другие.

Frontiers in Endocrinology, Год журнала: 2023, Номер 14

Опубликована: Авг. 1, 2023

Septic patients with diabetes mellitus (DM) are more venerable to subsequent complications and the resultant increase in associated mortality. Therefore, it is important make tailored clinical decisions for this subpopulation at admission.Data from large-scale real-world databases named Medical Information Mart Intensive Care Database (MIMIC) were reviewed. The least absolute selection shrinkage operator (LASSO) was performed 10 times cross-validation methods select optimal prognostic factors. Multivariate COX regression analysis conducted identify independent factors nomogram construction. internally validated via bootstrapping method externally by MIMIC III database receiver operating characteristic (ROC), calibration curves, decision curve (DCA), Kaplan-Meier curves robustness check.A total of 3,291 septic DM included study, 2,227 IV 1,064 database, respectively. In training cohort, 28-day all-cause mortality rate 23.9% DM. multivariate Cox reveals age (hazard ratio (HR)=1.023, 95%CI: 1.016-1.031, p<0.001), respiratory failure (HR=1.872, 1.554-2.254, Sequential Organ Failure Assessment score (HR=1.056, 1.018-1.094, p=0.004); base excess (HR=0.980, 0.967-0.992, p=0.002), anion gap (HR=1.100, 1.080-1.120, albumin (HR=0.679, 0.574-0.802, international normalized (HR=1.087, 1.027-1.150, p=0.004), red cell distribution width 1.021-1.092, p=0.001), temperature (HR=0.857, 0.789-0.932, glycosylated hemoglobin (HR=1.358, 1.320-1.401, p<0.001) admission established shows satisfied accuracy utility AUCs 0.870 internal validation 0.830 external cohort as well 0.820 shock subpopulation, which superior predictive value single SOFA score.Our results suggest that characteristics show an prediction short-term model can support intensive care unit physicians making better initial subpopulation.

Язык: Английский

Процитировано

4
Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis DOI Creative Commons

Chengdong Xia,

Yufeng Han, Chunhui Yin

и другие.

Frontiers in Endocrinology, Год журнала: 2023, Номер 14

Опубликована: Сен. 15, 2023

Aim This study aims to assess the association between sodium–glucose cotransporter type-2 inhibitor (SGLT-2i) treatment and muscle atrophy in patients with type 2 diabetes mellitus (T2DM). Methods We searched six databases from 1 January 2012 May 2023, without language restrictions. The primary outcome was muscle. Secondary outcomes were weight loss, weakness, malaise, or fatigue. Subgroup analyses performed according different definitions of muscle, duration, measurement methods. quality studies assessed using Cochrane tool. evidence Grading Recommendations, Assessment, Development Evaluations (GRADE) Results Nineteen randomized controlled trials (RCTs) involving 1,482 participants included. Compared control group, a meta-analysis showed that T2DM group treated SGLT-2i demonstrated statistically significant reductions lean body mass 0.66 (95% confidence interval (CI), −1.05 −0.27; p = 0.0009) skeletal 0.35 CI, −0.66 −0.04; 0.03). No deaths serious adverse events reported. included low. Conclusions may lead reduction strength compared group. However, there is still lack high-quality evaluate caused by SGLT-2i. Systematic review registration https://inplasy.com/inplasy-2022-12-0061/ , identifier 2022120061.

Язык: Английский

Процитировано

4